New imaging technique could let doctors see lung Cancer's inner workings in real time

NCT ID NCT02676050

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested whether two optical imaging agents could be used during a bronchoscopy to visualize activated neutrophils and a cancer-related protein called c-MET in lung tumors. Five participants with lung cancer received the agents through a special catheter while doctors used a miniaturized imaging fiber to detect signals. The goal was to explore whether this technique could provide real-time molecular insights into lung cancer, but the study was terminated early and was not designed to treat the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Optical imaging agents (EMI-137 and NAP)
What this could lead to
If successful, this approach could help doctors see specific cancer-related molecules in real time during a lung exam, potentially improving diagnosis or treatment guidance.
What could go wrong
This was a very small, early exploratory study that was terminated early. It was designed only to test imaging feasibility, not to treat or cure lung cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Royal Infirmary of Edinburgh

    Edinburgh, EH16 4TJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.